132 related articles for article (PubMed ID: 35112690)
1. Inhibition of tumor recurrence and metastasis
Lu Y; Wu C; Yang Y; Chen X; Ge F; Wang J; Deng J
Biomater Sci; 2022 Mar; 10(5):1352-1363. PubMed ID: 35112690
[TBL] [Abstract][Full Text] [Related]
2. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
3. Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination.
He T; Shi Y; Kou X; Shen M; Liang X; Li X; Wu R; You Y; Wu Q; Gong C
Biomaterials; 2023 Oct; 301():122218. PubMed ID: 37393695
[TBL] [Abstract][Full Text] [Related]
4. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.
Ye X; Liang X; Chen Q; Miao Q; Chen X; Zhang X; Mei L
ACS Nano; 2019 Mar; 13(3):2956-2968. PubMed ID: 30789699
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
6. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
7. Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy.
Ji P; Sun W; Zhang S; Xing Y; Wang C; Wei M; Li Q; Ji G; Yang G
Adv Sci (Weinh); 2023 Aug; 10(22):e2301789. PubMed ID: 37222047
[TBL] [Abstract][Full Text] [Related]
8. Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment.
Cheng Z; Xue C; Liu M; Cheng Z; Tian G; Li M; Xue R; Yao X; Zhang Y; Luo Z
Acta Biomater; 2023 Oct; 169():289-305. PubMed ID: 37544392
[TBL] [Abstract][Full Text] [Related]
9. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
[TBL] [Abstract][Full Text] [Related]
11. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
12. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
Song H; Huang P; Niu J; Shi G; Zhang C; Kong D; Wang W
Biomaterials; 2018 Mar; 159():119-129. PubMed ID: 29324304
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
16. Injectable Hydrogels Coencapsulating Granulocyte-Macrophage Colony-Stimulating Factor and Ovalbumin Nanoparticles to Enhance Antigen Uptake Efficiency.
Sun Z; Liang J; Dong X; Wang C; Kong D; Lv F
ACS Appl Mater Interfaces; 2018 Jun; 10(24):20315-20325. PubMed ID: 29808993
[TBL] [Abstract][Full Text] [Related]
17. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
18. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
19. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors.
Wang H; Najibi AJ; Sobral MC; Seo BR; Lee JY; Wu D; Li AW; Verbeke CS; Mooney DJ
Nat Commun; 2020 Nov; 11(1):5696. PubMed ID: 33173046
[TBL] [Abstract][Full Text] [Related]
20. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]